ArticleArthroplasty today2024
Early Identification of Poorly Performing Implants in Michigan With the Example of the Vanguard XP.
Article in Arthroplasty today, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Farewell.Arthroplasty today · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Arthroplasty registries play a critical role in improving the quality of care and performing post-market surveillance of medical devices. We report the Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) findings specific to the Biomet Vanguard XP bicruciate-retaining total knee implant. Methods: Data were collected from MARCQI's 2019 report (February 15, 2012, through December 31, 2018). Demographic data were analyzed to determine differences between Vanguard XP and all other implants. The cumulative percent revision (CPR) was computed from the survival function, S(t), using CPR(t) = 100∗(1 - S(t)). A log-rank test was used to assess differences in the CPR curve for the Vanguard XP and all other implants. Results: There were 148,832 knee arthroplasty cases in the MARCQI registry and 507 using Vanguard XP implant combinations. The unadjusted cumulative percent revision curve up to 5 years postoperatively for the Vanguard XP differed from all other implants ( Conclusions: The Vanguard XP experienced higher early failure rates than other TKA implants within the MARCQI registry. The development of thresholds and benchmarks for registry reporting in collaboration with industry could potentially save patients from the morbidity caused by implants that do not perform as well as anticipated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.